Skip to main content

Advertisement

Figure 1 | BMC Research Notes

Figure 1

From: Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat

Figure 1

Effect of losartan on the liver fibrosis development in the OLETF rats. (A): Microphotographs of the liver of CDAA-treated OLETF rats. (B): The fibrosis area was evaluated by an image-analyzer. Losartan (30 mg/kg/day) significantly suppressed the CDAA-induced liver fibrosis development in the OLETF rats. Noteworthy was the finding that this inhibitory effect was achieved even at a clinically comparable low dose. The data represent the mean ± SD (n = 5). *: Statistically significance between the indicated group (p < 0.01).

Back to article page